SS-31 (Elamipretide)

SS-31, now known by the generic name elamipretide and marketed under the brand name Forzinity, is a synthetic tetrapeptide developed by Hazel Szeto and Peter Schiller, whose alternating aromatic and cationic amino acid design (D-arginine, 2',6'-dimethyltyrosine, lysine, phenylalanine, C-terminally amidated) was originally discovered during unrelated opioid receptor research in the early 2000s. Rather than acting on a cell-surface receptor, elamipretide targets a structural lipid, cardiolipin, that is concentrated almost exclusively in the inner mitochondrial membrane. This mechanism sets it apart from every receptor-targeted peptide elsewhere in this queue and places it in a distinct pharmacological category sometimes called mitochondria-targeted or Szeto-Schiller peptides. After roughly two decades of development spanning acute cardiac injury, chronic heart failure, primary mitochondrial disease, and retinal disease, elamipretide received its first FDA approval in September 2025, an accelerated approval specifically for improving muscle strength in Barth syndrome, an ultra-rare inherited disorder of cardiolipin metabolism. This makes elamipretide one of only a handful of peptides in this queue with genuine regulatory approval, though that approval is narrow, recent, and explicitly conditional on a confirmatory trial.

The core molecular mechanism is cardiolipin binding. Cardiolipin is a uniquely shaped, four-acyl-chain phospholipid that anchors and organizes the protein complexes of the electron transport chain, curves the inner mitochondrial membrane into cristae folds, and, under oxidative stress, can be co-opted by cytochrome c into a peroxidase reaction that generates damaging reactive oxygen species and triggers programmed cell death. Elamipretide accumulates in the inner mitochondrial membrane through electrostatic attraction between its cationic residues and the negatively charged mitochondrial environment, a targeting mechanism that, unlike some other mitochondria-directed compounds, does not require an intact mitochondrial membrane potential and therefore continues to work in already-stressed or partially depolarized mitochondria. Once localized, its dimethyltyrosine residue inserts into cardiolipin acyl chains while its cationic residues engage the phosphate headgroups, stabilizing cardiolipin structural role, preventing the peroxidase reaction with cytochrome c, and supporting proper assembly of the multiprotein respiratory supercomplexes that cardiolipin normally organizes.

The strongest and most consequential human evidence comes from the TAZPOWER Barth syndrome program, though it illustrates a pattern that recurs across nearly every elamipretide trial: primary endpoints tend to miss statistical significance in the randomized, placebo-controlled phase of a trial, while positive findings emerge later in open-label extension follow-up. The initial randomized crossover phase of TAZPOWER (n=12) did not meet its six-minute walk test or symptom-score primary endpoints; those measures turned positive only at week 36 of open-label extension, and the muscle-strength finding that ultimately supported FDA approval emerged from data collected out to 168 weeks of open-label, uncontrolled follow-up. A near-identical pattern appears in the phase 3 MMPOWER-3 trial for primary mitochondrial myopathy, where the overall randomized population showed no significant benefit but a genetically defined subgroup did, and in the phase 2 ReCLAIM-2 macular degeneration trial, where the co-primary endpoints missed but a secondary visual acuity measure reached nominal significance. Readers should recognize this as a distinct and important evidence-quality issue: elamipretide has substantially more human randomized trial data than most peptides in this queue, but that data has repeatedly required a fallback endpoint, subgroup, or extension analysis to demonstrate benefit, a materially different situation from either a clean positive trial or a purely preclinical evidence base.

Practically, elamipretide is administered by subcutaneous injection, most commonly at 40 mg once daily, and cannot be taken orally because peptide bonds of this size are rapidly broken down by digestive enzymes. Its FDA label reports an unusually efficient subcutaneous absorption of approximately 92 percent, a notably higher figure than many other subcutaneously injected peptides, with elimination almost entirely through the kidneys as inactive breakdown products. Injection-site reactions, particularly redness, pain, induration, and itching, are reported in the large majority of treated patients and represent the most consistent safety finding across the program, though no boxed warning or major systemic toxicity signal has emerged. As an FDA-approved product, Forzinity is manufactured and quality-controlled to pharmaceutical standards; elamipretide sold under the research name "SS-31" through unregulated peptide vendors carries none of those assurances and should not be equated with the approved drug used in every trial described here.

Mechanism of Action

Structure and Membrane-Potential-Independent Mitochondrial Targeting

Elamipretide is a synthetic tetrapeptide, D-arginine-2’,6’-dimethyltyrosine-lysine-phenylalanine, with a C-terminal amide. Its defining structural feature is the alternation of aromatic residues (dimethyltyrosine, phenylalanine) with cationic residues (D-arginine, lysine), a motif first identified by Hazel Szeto and Peter Schiller during unrelated opioid receptor research. This alternating architecture allows elamipretide to accumulate several thousandfold in the inner mitochondrial membrane relative to the surrounding cytoplasm. Critically, this targeting mechanism does not depend on the mitochondrial membrane potential. Other mitochondria-directed compounds, such as those conjugated to a triphenylphosphonium cation, rely on the negative-inside voltage gradient across the inner membrane to drive their accumulation, and that targeting mechanism fails precisely when mitochondria are most stressed and depolarized. Elamipretide, by contrast, continues to localize to the inner membrane even under depolarizing conditions, which is the pharmacological rationale for testing it in acute ischemic and chronically failing tissue where membrane potential is already compromised.

Cardiolipin Binding and Structural Stabilization

Once localized to the inner mitochondrial membrane, elamipretide binds reversibly and with high affinity to cardiolipin, a phospholipid with four acyl chains found almost exclusively in that membrane and required for the structural organization of the electron transport chain. The binding interaction combines electrostatic attraction, between elamipretide’s cationic arginine and lysine residues and cardiolipin’s negatively charged phosphate headgroups, with a hydrophobic component, in which the dimethyltyrosine residue inserts among cardiolipin’s acyl chains. Cardiolipin normally curves the inner membrane into the folded cristae structures where respiratory complexes are embedded, and elamipretide binding is proposed to stabilize this curvature and prevent cardiolipin from adopting the conformations associated with mitochondrial dysfunction.

Preventing the Cardiolipin-Cytochrome c Peroxidase Reaction

Under oxidative stress, cytochrome c can bind cardiolipin and, in that bound state, acquire peroxidase activity that generates reactive oxygen species and oxidizes cardiolipin itself. Oxidized cardiolipin then detaches from the inner membrane and translocates toward the outer membrane, an early step in the intrinsic apoptotic pathway that leads to cytochrome c release and cell death. By stabilizing cardiolipin’s normal conformation and its association with the inner membrane, elamipretide is proposed to interfere with this peroxidase reaction, reducing both reactive oxygen species generation and the downstream trigger for programmed cell death. This mechanism was first demonstrated in cell culture and rodent ischemia-reperfusion models in the foundational 2004 paper by Zhao and colleagues, which showed reduced oxidative cell death and reduced mitochondrial swelling with SS-31 treatment.

Respiratory Supercomplex Assembly

Cardiolipin is required for the stable assembly of respiratory chain supercomplexes, higher-order structures in which individual Complex I, III, and IV units associate into larger assemblies sometimes called respirasomes. Two mitochondrially encoded electron transport chain subunits, MT-ND4 (part of Complex I) and MT-CO3 (part of Complex IV), have documented cardiolipin-dependent stability and supercomplex incorporation. By preserving cardiolipin’s structural and biochemical integrity, elamipretide is mechanistically linked to supporting the assembly and stability of these supercomplexes, which is proposed to improve the efficiency of electron transfer between complexes and reduce the electron leak that generates reactive oxygen species when the chain is poorly organized. This proposed downstream effect on supercomplex assembly has not been directly measured in every elamipretide trial and remains an inference from cardiolipin biology rather than a universally confirmed clinical finding.

Mitochondrial Dynamics Normalization in Heart Failure Tissue

In chronic heart failure, mitochondria show characteristic structural abnormalities, including disorganized cristae and an imbalance between the fission and fusion proteins that normally maintain a healthy mitochondrial network, of which OPA1 is a central inner-membrane fusion mediator whose function itself depends on adequate cardiolipin. A study combining a canine model of chronic heart failure with ex vivo tissue from human failing hearts found that several months of elamipretide exposure normalized these cristae abnormalities and restored a more typical fission-fusion protein balance. This is a tissue-level, mechanistic finding from an animal model and human tissue samples studied outside the body, not a demonstration that living heart-failure patients experience improved cardiac function, a distinction borne out by the shorter human PROGRESS-HF trial described in Clinical Evidence below.

Clinical Evidence

Barth Syndrome and the TAZPOWER Program (FDA-Approval Basis)

Barth syndrome is caused by mutations in the TAZ gene encoding tafazzin, an enzyme required to remodel cardiolipin into its mature, functional form; without functional tafazzin, cardiolipin accumulates in an abnormal, immature state that destabilizes mitochondrial cristae and the respiratory chain. This direct disease link to cardiolipin biology made Barth syndrome the natural first target for a cardiolipin-stabilizing peptide. The TAZPOWER trial (Thompson et al., 2021, PMID 33077895) enrolled 12 patients with genetically confirmed Barth syndrome in a randomized, double-blind, placebo-controlled crossover design, with 12-week treatment periods on 40 mg subcutaneous elamipretide daily separated by a 4-week washout. Neither prespecified primary endpoint, the six-minute walk test nor the Barth Syndrome Symptom Assessment, reached statistical significance during these randomized periods. Patients were then followed in an open-label extension, and at week 36 the six-minute walk test had improved by 95.9 meters (a statistically significant change, p=0.024) alongside a significant symptom-score improvement. A subsequent 168-week open-label extension analysis (Thompson et al., 2024, PMID 38602181) reported improvement in knee extensor muscle strength, and this intermediate endpoint became the basis for the FDA’s accelerated approval of Forzinity in September 2025, specifically for improving muscle strength in Barth syndrome patients weighing at least 30 kg.

Primary Mitochondrial Myopathy (MMPOWER Program)

Primary mitochondrial myopathy encompasses a genetically heterogeneous group of disorders, caused by mutations in either mitochondrial DNA or nuclear genes encoding mitochondrial proteins, that impair muscle energy metabolism and cause exercise intolerance and fatigue. An earlier randomized crossover trial (Karaa et al., 2020, PMID 32096613) provided initial human dosing and outcome data in this population. The pivotal phase 3 trial, MMPOWER-3 (Karaa et al., 2023, PMID 37268435), randomized 218 adults with genetically confirmed primary mitochondrial myopathy to 24 weeks of 40 mg subcutaneous elamipretide daily or placebo. The trial did not meet its co-primary endpoints, the six-minute walk test and a mitochondrial-disease-specific fatigue scale, across the full genotypically mixed population. A prespecified subgroup of participants with nuclear DNA (rather than mitochondrial DNA) pathogenic variants did show a significant six-minute walk test improvement. A 2024 post hoc genotype-specific reanalysis (Karaa et al., PMID 39574155) narrowed this apparent benefit further, to patients with pathogenic variants affecting the mitochondrial DNA replisome (the replication machinery) and to those with chronic progressive external ophthalmoplegia. This genotype-narrowing result has motivated a follow-up trial targeting this more specific population rather than supporting a broader approval in primary mitochondrial myopathy generally.

Heart Failure with Reduced Ejection Fraction

Chronic heart failure is associated with impaired myocardial energy metabolism and mitochondrial dysfunction, providing a mechanistic rationale for testing a cardiolipin-stabilizing peptide in this population. The phase 2 PROGRESS-HF trial (Butler et al., 2020, PMID 32068002) randomized 71 patients with heart failure with reduced ejection fraction to placebo, 4 mg, or 40 mg subcutaneous elamipretide once daily for 4 weeks, with the primary endpoint being change in left ventricular end-systolic volume measured by cardiac magnetic resonance imaging. Neither elamipretide dose significantly improved this endpoint compared with placebo. This human result stands in contrast to the tissue-level mitochondrial normalization observed in the canine and ex vivo human heart-failure study described in Mechanism of Action above, and it remains an open question whether the shorter 4-week duration of PROGRESS-HF, relative to the several-month exposure used in the mechanistic tissue study, was sufficient to allow a clinical effect to emerge.

Age-Related Macular Degeneration and Geographic Atrophy

Photoreceptor and retinal pigment epithelial cells have high mitochondrial density and energy demand, making age-related macular degeneration, particularly its geographic atrophy form, another mechanistically plausible target for elamipretide despite the unusual choice of a systemic subcutaneous injection to treat an eye disease. A phase 1 open-label trial (Mettu et al., 2022, PMID 36246181) established safety and feasibility of daily subcutaneous elamipretide in patients with noncentral geographic atrophy. The subsequent phase 2 ReCLAIM-2 trial (Ehlers et al., 2025, PMID 39605874) randomized patients to 48 weeks of daily subcutaneous elamipretide or placebo, with co-primary endpoints of low-luminance visual acuity change and geographic atrophy area growth measured by optical coherence tomography. Neither co-primary endpoint reached statistical significance. A secondary analysis found that 14.6 percent of elamipretide-treated patients gained 10 or more letters of low-luminance visual acuity, compared with 2.1 percent on placebo, a difference reaching nominal statistical significance (p=0.0404) but not adjusted for the trial’s co-primary endpoint structure, meaning it should be read as a promising secondary signal rather than a confirmed treatment effect.

Acute Myocardial Infarction and Reperfusion Injury

The earliest clinical hypothesis for SS-31 targeted acute ischemia-reperfusion injury, the burst of oxidative damage that occurs when blood flow is restored to heart tissue after a heart attack, a setting where the membrane-potential-independent targeting mechanism described above was thought to be particularly advantageous. The EMBRACE-STEMI trial tested intravenous MTP-131 (an earlier name for elamipretide) in patients undergoing emergency angioplasty for anterior ST-elevation myocardial infarction, measuring myocardial infarct size using serial cardiac biomarkers. The trial found no reduction in infarct size compared with placebo. Unlike the mixed-but-suggestive results seen in Barth syndrome, primary mitochondrial myopathy, and geographic atrophy, this was an unambiguously negative result, and the acute myocardial infarction indication was not pursued further in later development.

Safety and Tolerability

Across the elamipretide clinical program, the dominant and most consistent adverse finding is injection-site reactions. In the trial population supporting FDA approval, injection-site erythema occurred in essentially all elamipretide-treated patients compared with a quarter of placebo-treated patients, with injection-site pain, induration, and pruritus each occurring in roughly two-thirds to three-quarters of treated patients, substantially more often than with placebo. These reactions are generally manageable with oral antihistamines or topical corticosteroids per the FDA-approved prescribing information. No boxed warning appears on the label, and no consistent pattern of serious systemic toxicity, hepatotoxicity, or hematologic abnormality has emerged across the Barth syndrome, mitochondrial myopathy, heart failure, or macular degeneration programs. Because elamipretide and its inactive M1 and M2 metabolites are cleared almost entirely through the kidneys, with systemic exposure rising substantially in renal impairment, renal function assessment and monitoring are clinically relevant considerations not fully captured by the injection-site-focused adverse event profile.

Regulatory Status

Elamipretide, under the brand name Forzinity, received FDA accelerated approval in September 2025, specifically indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. This approval is narrow in three distinct respects that should not be blurred together: it is limited to a single ultra-rare disease, it is limited to patients above a specific body weight, and it rests on an intermediate endpoint (knee extensor muscle strength observed in open-label follow-up) rather than a randomized, placebo-controlled demonstration of the same benefit. Accelerated approval carries a formal condition, disclosed by the manufacturer, that continued approval for this indication may depend on verification of clinical benefit in a confirmatory trial. Outside the Barth syndrome indication, elamipretide is not FDA-approved for any use, including primary mitochondrial myopathy, heart failure, acute myocardial infarction, or geographic atrophy, despite having been tested in randomized human trials for each of these. Elamipretide is not listed as a substance of particular doping concern by the World Anti-Doping Agency in the way that growth-hormone-axis or anabolic peptides are, but this reflects its mechanism rather than a specific safety clearance for unsupervised use. Elamipretide obtained outside the approved Forzinity product, commonly sold under the research name “SS-31” through peptide vendors without pharmaceutical manufacturing oversight, carries none of the sterility, potency, or purity assurances of the approved drug and should not be treated as clinically equivalent to it.

SS-31 versus MOTS-c

Elamipretide and MOTS-c are grouped together in discussions of mitochondria-targeted peptides, but they act through unrelated mechanisms and occupy very different positions on the evidence spectrum. Elamipretide is a synthetic tetrapeptide that physically binds cardiolipin, a structural lipid, in the inner mitochondrial membrane, and it has been tested in numerous randomized human trials culminating in a narrow FDA approval for Barth syndrome. MOTS-c is a naturally occurring, mitochondrial-DNA-encoded peptide that acts on cellular energy-sensing pathways, primarily AMPK, and its evidence base remains almost entirely preclinical, with no completed randomized human efficacy trial. Where elamipretide’s central evidence-quality issue is a recurring pattern of missed randomized primary endpoints followed by positive open-label or subgroup findings, MOTS-c’s central evidence-quality issue is the near-total absence of human trial data of any kind. Neither peptide should be assumed interchangeable with the other based on a shared “mitochondrial peptide” label.

Dosing Guidance

The only FDA-approved dosing regimen for elamipretide is 40 mg administered by subcutaneous injection once daily, as Forzinity, for the treatment of muscle strength deficits in Barth syndrome patients weighing at least 30 kilograms; this is the dose and route used across the TAZPOWER program that supported approval. The same 40 mg subcutaneous daily dose was used in the MMPOWER-3 primary mitochondrial myopathy trial and the ReCLAIM-2 macular degeneration trial, neither of which met its primary endpoint. The phase 2 PROGRESS-HF heart failure trial additionally tested a lower 4 mg subcutaneous daily dose without demonstrating benefit over 4 weeks at either dose. No dose above 40 mg subcutaneous daily has been systematically studied in humans, and the early intravenous dosing scheme used in the discontinued EMBRACE-STEMI acute myocardial infarction program is not directly comparable to subcutaneous dosing and was not carried into later development. Because renal clearance governs elamipretide elimination, dosing in patients with reduced kidney function should follow the specific guidance in the current FDA-approved prescribing information rather than the flat 40 mg figure used in the general trial population.